Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use
© 2018 Royal Pharmaceutical Society Objectives: The use of doxorubicin, an antineoplastic medication used for the treatment of cancers via mechanisms that prevent replication of cells or lead to their death, can result in damage to healthy cells as well as malignant. Among the affected cells are me...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Published: |
John Wiley & Sons Ltd.
2018
|
| Online Access: | http://hdl.handle.net/20.500.11937/67187 |